Terpos E, Voskaridou E (2010) Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 1202(1):237–43Terpos, E.; Voskaridou, E. Treatment options for thalassemia patients with osteoporosis. Ann. N. Y. Acad. Sci. 2010, 1202, 237-243....
iron. Iron overload is a leading cause of mortality and organ injury. The only treatment options for removing excess iron are phlebotomy and chelation. While phlebotomy is a very effective way of removing iron, it is not appropriate for patients with thalassemia except after bone marrow ...
The only treatment options for removing excess iron are phlebotomy and chelation. While phlebotomy is a very effective way of removing iron, it is not appropriate for patients with thalassemia except after bone marrow transplantation. The segment is projected to expand at an exponential growth rate ...
Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease. Allogeneic stem cell transplantation and gene therapy are available only for a minority of patients, are as...
GDF11 is a key inhibitor of late-stage erythroid differentiation, which has been shown to be upregulated in MDS and MF patients.56 Luspatercept has been already approved for the treatment of anemia in myelodysplastic syndrome (MDS) and beta thalassemia, but is now being studied in patients ...
Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease 2023, European Journal of Pediatrics Diverse Approaches to Gene Therapy of Sickle Cell Disease 2023, Annual Review of Medicine Engineered BMSCs-Derived Exosomal miR-542-3p Promotes Cutaneous Wound Healing...
FJ Kirkham,MR Debaun - 《Current Treatment Options in Neurology》 被引量: 115发表: 2004年 Iron overload in thalassemia and sickle cell disease Current treatment and understanding of sickle cell disease require an appreciation for the complexity of its basic pathophysiology. The clinical manifestat....
Secondary solid cancer following hematopoietic cell transplantation in patients with thalassemia major Hematopoietic cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers (SSCs). The aim of this retrospective study was to compare the incidence of SSC in a monocentr...
“Patients diagnosed with advanced or metastasized ESCC, the most common histologic subtype of esophageal cancer, often progress following initial therapy and are in need of new options,” Syma Iqbal, M.D., Associate Professor of Clinical Medicine, Section Chief Gastrointestinal Oncology, Division of...
So patients continued searching for medical options. "So previously the only cure for thalassemia was a bone marrow transplant," he said. But match donors are not always available. That’s why this current medical breakthrough is what doctors were advocating for. "It involves takin...